CAI insider ownership: who sold, why, and what they still hold

What stands out

Brian Brille sold $12.1M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Sep 17, 2026

Four insiders bought shares: Jon Halbert (68K shares, $990K), Jeff Vacirca (31K shares, $501K) and John Denton (4.2K shares, $101K), plus 1 more.Jon Halbert: purchase, May 15, 2026 · Jeff Vacirca: purchase, May 11, 2026 · John Denton: purchase, Nov 7, 2025

Selling picked up in the last 90 days: officers and directors sold 1.00M shares, against an average of 20K per 90 days earlier in the period. Most of it was David Spetzler (597K shares in the last 90 days) and Brian Brille (400K shares in the last 90 days); 0% of these sales were under disclosed plans.David Spetzler: largest recent sale, Sep 3, 2026 · Brian Brille: largest recent sale, Sep 17, 2026

A share of stake is shown for 0 of the 4 officers and directors who sold. 15 are left out

Left out: David Halbert, Peter Castleman, Jon Halbert, Brian Brille, George Poste, David Spetzler, Laura Johansen, Jonathan Knowles, John Denton, Danny Phillips, Luke Power, Lloyd Minor, David Fredrickson, Joseph Gilliam and Jeff Vacirca (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

David Spetzler

President

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$14.8MTo cover taxes

Brian Brille

Vice Chairman and Executive Vice President, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$12.1MNo plan disclosed

Luke Power

Senior Vice President, Chief Financial Officer, and Chief Accounting Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.7MDisclosed plan

John Denton

Senior Vice President, General Counsel, and Secretary

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$239KNo plan disclosed

Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

Sep 22, 2026John Denton sold 7.5K shares ($239K) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
John Denton Senior Vice President, General Counsel, and Secretary	7,500	$31.82	n/a	n/a	Sep 22, 2026	Sep 23, 2026

Sep 17, 2026Brian Brille sold 400K shares ($12.1M) with no plan disclosed. 400K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Brian Brille Vice Chairman and Executive Vice President, Director	400,000	$30.33	n/a	n/a	Sep 17, 2026	Sep 17, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

TSSP Sub-Fund HoldCo LLC and Whitney J reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Caris Life Sciences, Inc. CEO selling stock?

No. David Halbert reported no open-market sales in the past 12 months.

Why are Caris Life Sciences, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 6% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 51% were to cover taxes and 43% had no disclosed plan. A trading plan schedules sales in advance.

Are any Caris Life Sciences, Inc. insiders buying?

Yes. 4 officers or directors reported 4 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold4 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
David Spetzler President	$14.8M 597K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Brian Brille Vice Chairman and Executive Vice President, Director	$12.1M 400K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Luke Power Senior Vice President, Chief Financial Officer, and Chief Accounting Officer	$1.7M 62K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
John Denton Senior Vice President, General Counsel, and Secretary	$239K 7.5K shares	Not confirmed share of stake is being verified. Why	No plan disclosed

Outside holder, reported separately: TSSP Sub-Fund HoldCo LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Whitney J (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 15 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

David Halbert

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for David Halbert are complete.

Founder, Chairman, and Chief Executive Officer, Director

n/a

Vesting, gifts, unvested awards and holding lines for David Halbert

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Halbert are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−41Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,000,000	$2.44	Nov 14, 2028	$58.8M

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

Peter Castleman

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Peter Castleman are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Peter Castleman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Peter Castleman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Jon Halbert

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jon Halbert

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jon Halbert are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Brian Brille

Vice Chairman and Executive Vice President, Director

n/a

−400K

n/a

Vesting, gifts, unvested awards and holding lines for Brian Brille

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brian Brille are complete; balances and unit counts will be added when the check is finished.

−1.3Kgifted (net of own trusts)

−14Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,600,000	$2.44	Jan 14, 2028	$47.0M
1,000,000	$8.00	Feb 26, 2030	$23.8M
437,500	$16.20	Aug 11, 2032	$6.8M

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

George Poste

Director

n/a

Vesting, gifts, unvested awards and holding lines for George Poste

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for George Poste are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
125,000	$2.44	Sep 15, 2025	$3.7M
50,000	$2.44	Sep 12, 2026	$1.5M

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

David Spetzler

President

n/a

−597K

n/a

Vesting, gifts, unvested awards and holding lines for David Spetzler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Spetzler are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−14Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
750,000	$18.60	Mar 3, 2035	$9.9M
1,000,000	$8.00	Apr 1, 2030	$23.8M

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

Laura Johansen

Director

n/a

Vesting, gifts, unvested awards and holding lines for Laura Johansen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Laura Johansen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Jonathan Knowles

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jonathan Knowles

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Knowles are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,500	$16.20	Aug 9, 2033	$39K

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

John Denton

Senior Vice President, General Counsel, and Secretary

n/a

−7.5K

n/a

Vesting, gifts, unvested awards and holding lines for John Denton

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Denton are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−6Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
255,000	$18.60	Mar 3, 2035	$3.4M

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

Danny Phillips

Director

n/a

Vesting, gifts, unvested awards and holding lines for Danny Phillips

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Danny Phillips are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,500	$18.60	Feb 27, 2035	$33K

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

Luke Power

Senior Vice President, Chief Financial Officer, and Chief Accounting Officer

n/a

−62K

n/a

Vesting, gifts, unvested awards and holding lines for Luke Power

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Luke Power are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−9.8Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$8.00	Feb 26, 2030	$238K
12,500	$8.00	Nov 19, 2030	$298K
6,250	$12.84	May 20, 2031	$119K
5,031	$12.84	Sep 24, 2031	$95K
62,500	$16.20	Aug 11, 2032	$976K
249,999	$16.20	May 17, 2033	$3.9M

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

Lloyd Minor

Director

n/a

Vesting, gifts, unvested awards and holding lines for Lloyd Minor

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lloyd Minor are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

David Fredrickson

Director

n/a

Vesting, gifts, unvested awards and holding lines for David Fredrickson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Fredrickson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
75,000	$19.44	Aug 14, 2034	$928K
2,500	$18.60	Feb 27, 2035	$33K

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

Joseph Gilliam

Director

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Gilliam

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Gilliam are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
75,000	$8.00	Apr 8, 2031	$1.8M
2,500	$18.60	Feb 27, 2035	$33K

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

Jeff Vacirca

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jeff Vacirca

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeff Vacirca are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,000	$17.16	Feb 23, 2032	$366K
75,000	$19.44	Nov 7, 2034	$928K

Estimate: options held × ($31.82 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close.

Holdings and share of stake for Caris Life Sciences, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$28.9M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $28.9M across 1,066,962 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $1.7M · 6%

94%

The lighter segment is sales with no plan disclosed in the filing ($27.2M), including tax-related sales outside a plan.

No plan disclosed · $12.4M

Sales with no 10b5-1 plan and no tax reference in the filing. $12.1M of it is Brian Brille. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Brian Brille, Sep 17, 2026

Taxes

$14.8M of sales (51.4%) cite tax obligations in their footnotes. Separately, 84,373 shares ($1.3M) were withheld by the company for taxes, which isn't a market sale. Example: David Spetzler, Sep 4, 2026

Purchases · 4 buyers (4 trades)

4 officers and directors bought shares in this period, in 4 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 6 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
David Spetzler President	597K	$14.8M	0%	51%	Sep 3, 2026 to Sep 4, 2026
Brian Brille Vice Chairman and Executive Vice President, Director	400K	$12.1M	0%	42%	Sep 17, 2026 to Sep 17, 2026
Luke Power Senior Vice President, Chief Financial Officer, and Chief Accounting Officer	62K	$1.7M	100%	6%	Dec 11, 2025 to Dec 11, 2025
John Denton Senior Vice President, General Counsel, and Secretary	7.5K	$239K	0%	0.8%	Sep 22, 2026 to Sep 22, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$1.7M	$1.7M	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$27.2M	$0	$14.8M	$12.4M
Oct 2026	$0	$0	$0	$0

Known gaps and uncertainty15 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Caris Life Sciences, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology67 filings on record, 36 filed in the 12-month period, and how we read them

All 67 Forms 3, 4 and 5 on record for Caris Life Sciences, Inc. (SEC CIK 2019410), filed from Jun 17, 2025 to Sep 23, 2026; 36 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Caris Life Sciences, Inc. insiders sold $28.9M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Caris Life Sciences, Inc. CEO selling stock?

Why are Caris Life Sciences, Inc. insiders selling?

Are any Caris Life Sciences, Inc. insiders buying?

The evidence

No plan disclosed · $12.4M

Taxes

Purchases · 4 buyers (4 trades)

Sales by month